Dudediligence.

Soligenix, Inc

SNGXNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Net income, by quarter
−$1.7MSep ’24−$3.0MDec ’24−$3.0MMar ’25−$2.7MJun ’25−$2.5MSep ’25−$2.9MDec ’25−$2.8MMar ’26−$2.0MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$824,268$948,911$839,359$119,371none on file
Gross profit$95,628$398,089$97,311$0.00none on file
Operating income−$13.1M−$14.2M−$7.7M−$9.4M−$11.8M
Net income−$12.6M−$13.8M−$6.1M−$8.3M−$11.1M
Operating cash flow−$11.7M−$12.6M−$8.6M−$8.4M−$10.3M
Free cash flownone on filenone on filenone on filenone on file−$10.3M
Cash$26.0M$13.4M$8.4M$7.8M$7.9M
Debtnone on file$0.00$1.0M$0.00none on file
Shares outstanding2.9M2.9M648.8K2.5M10.1M